The clinical significance of decreased T cell interleukin-2 production in systemic lupus erythematosus: Connecting historical dots

Arthritis and Rheumatism

Volumn 62, Issue 8, 2010, Pages 2185-2187

  Horwitz, David A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTINUCLEAR ANTIBODY; ARGININE; CD4 ANTIGEN; DOUBLE STRANDED DNA ANTIBODY; GLYCOGEN SYNTHASE KINASE 3; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; LITHIUM CHLORIDE; STAT5A PROTEIN; STAT5B PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN ANTIBODY COMPLEX; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL MIGRATION; CELL PERMEABILIZATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE PREDISPOSITION; EDITORIAL; ENZYME SYNTHESIS; HOMEOSTASIS; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNE STATUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MITOGENESIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TH17 CELL;

HUMANS; INTERLEUKIN-2; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES;

EID: 77955353617     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27538     Document Type: Editorial

References (19)

1. Song YC, Tang SJ, Lee TP, Hung WC, Lin SC, Tsai CY, et al. Reversing interleukin-2 inhibition by anti-double-stranded DNA autoantibody ameliorates glomerulonephritis in MRL-lpr/lpr mice. Arthritis Rheum 2010;62:2401-11.
2. + regulatory T cells. J Immunol 2007;178:280-90.
3. Wei L, Laurence A, O'Shea JJ. New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin Cell Dev Biol 2008;19:394-400.
4. Horwitz DA. Regulatory T cells in systemic lupus erythematosus: past, present and future. Arthritis Res Ther 2008;10:227.
5. Alarcon-Segovia D, Ruiz-Arguelles A, Fishbein E. Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors. Nature 1978;271:67-9. (Pubitemid 8240067)
6. Putterman C. New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus. Autoimmun Rev 2004;3:7-11. (Pubitemid 38293360)
7. Sun KH, Yu CL, Tang SJ, Sun GH. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1β, IL-6, IL-8, IL-10 and TNF-α from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 2000;99:352-60.
8. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007;32:577-95. (Pubitemid 46481289)
9. Froncek MJ, Horwitz DA. Cytokines in the pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 187-203.
10. Horwitz DA, Cousar JB. A relationship between impaired cellular immunity humoral suppression of lymphocyte function and severity of systemic lupus erythematosus. Am J Med 1975;58:829-35.
11. Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005;115:996-1005. (Pubitemid 40489404)
12. Linker-Israeli M, Bakke AC, Quismorio FP Jr, Horwitz DA. Correction of interleukin-2 production in patients with systemic lupus erythematosus by removal of spontaneously activated suppressor cells. J Clin Invest 1985;75:762-8. (Pubitemid 15142091)
13. Linker-Israeli M, Quismorio FP Jr, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990;33:1216-25. (Pubitemid 20273310)
14. La Cava A, Fang CJ, Singh RP, Ebling F, Hahn BH. Manipulation of immune regulation in systemic lupus erythematosus. Autoimmun Rev 2005;4:515-9. (Pubitemid 41415762)
15. Kang HK, Michaels MA, Berner BR, Datta SK. Very low dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 2005;174:3247-55.
16. + Treg cells are associated with immunological remission of lupus. J Immunol 2009;183:6346-58.
17. Via CS, Shearer GM. Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus. Autoimmunity 2010;43:23-31.
18. Koshy M, Berger D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826-37. (Pubitemid 26349188)
19. Pugh-Bernard AE, Cambier JC. B cell receptor signaling in human systemic lupus erythematosus. Curr Opin Rheumatol 2006;18:451-5.